A resolution supporting the goals and ideals of World Sickle Cell Awareness Day.

Bill: 117-sres-683
Sponsor: full_name: Sen. Booker, Cory A. [D-NJ]
Introduced: 2022-06-16
Policy area: International Affairs
Latest action: action_date: 2022-06-16
text: Referred to the Committee on Foreign Relations.

Summaries:
action_date: 2022-06-16
action_desc: Introduced in Senate
text: <p>This resolution supports the goals and ideals of World Sickle Cell Awareness Day.</p> <p>The resolution also commits to ensuring equitable access to new sickle cell disease (SCD) treatments by shining the light among all economic, racial, and ethnic groups to improve health outcomes for those living with SCD. </p> <p>Finally, the resolution encourages the people of the United States and the world to hold appropriate programs, events, and activities on Sickle Cell Awareness Day to raise public awareness of SCD traits, preventative care programs, treatments, and other patient services for those suffering from SCD, complications from SCD, and conditions related to SCD. </p>

tv_txt: III 117th CONGRESS 2d Session S. RES. 683 IN THE SENATE OF THE UNITED STATES June 16, 2022 Mr. Booker (for himself, Mr. Brown , and Mr. Van Hollen ) submitted the following resolution; which was referred to the Committee on Foreign Relations RESOLUTION Supporting the goals and ideals of World Sickle Cell Awareness Day.

Whereas sickle cell disease (referred to in this preamble as SCD ) is a genetically inherited condition present at birth that involves a group of red blood cell disorders and is a major health problem in the United States and worldwide; Whereas the 2022 theme of World Sickle Cell Awareness Day, Shine the Light on Sickle Cell , is an immediate call to action to improve the health and quality of life for individuals living with SCD and their families; Whereas, in 1972, Dr. Charles Whitten established the Sickle Cell Disease Association of America, which is now headquartered in Hanover, Maryland, to improve research, education, and healthcare for SCD patients; Whereas, in 1972, Congress passed the National Sickle Cell Anemia Control Act ( Public Law 92–294 ; 86 Stat. 136), which provided authority to establish education, information, screening, testing, counseling, research, and treatment programs for SCD patients; Whereas SCD is a genetic mutation that causes a single misspelling in the DNA instructions for hemoglobin, a protein that aids in carrying oxygen in the blood, which may result in chronic complications related to anemia, stroke, infections, organ failure, tissue damage, intense periods of pain referred to as vaso-occlusive crisis, and premature death; Whereas sickle cell trait (referred to in this preamble as SCT ) occurs when an individual inherits one copy of the sickle cell gene from one parent, and when both parents have SCT, there is a 25 percent chance that any of their children will have SCD; Whereas there are an estimated 3,000,000 individuals with SCT in the United States, with many unaware of their status; Whereas an estimated 100,000 individuals have SCD in the United States, with 1 out of 365 African-American births and 1 out of 16,300 Hispanic-American births resulting in SCD, and nearly 1 out of 13 African-American babies are born with SCT; Whereas SCD affects millions of people throughout the world, especially individuals of genetic descent from sub-Saharan regions of Africa, South America, the Caribbean, Central America, Saudi Arabia, India, Turkey, Greece, and Italy; Whereas the prevalence of SCT varies greatly by region, with rates as high as 40 percent in certain regions of sub-Saharan Africa, eastern Saudi Arabia, and central India; Whereas, in many countries that are poor in resources, more than 90 percent of children with SCD do not live to see adulthood; Whereas approximately 1,000 children in Africa are born with SCD each day, more than half of whom will die before their fifth birthday; Whereas the high prevalence of SCD in the central and western regions of India results in approximately 20 percent of babies diagnosed with SCD dying before the age of 2; Whereas, in 2006, the World Health Assembly passed a resolution, adopted by the United Nations in 2009, recognizing SCD as a public health priority with a call to action that each country implement measures to tackle the disease; Whereas screening newborns for SCD is a crucial first step for families to obtain a timely diagnosis and comprehensive care and to decrease the mortality rate of children with SCD; Whereas approved treatments for SCD are limited, with the Food and Drug Administration approving only 4 SCD therapies since 2017, but there are more than 40 SCD therapies in development; Whereas there is an immediate need for lifesaving therapeutics that can improve the duration and quality of life of individuals with SCD; Whereas, in 2020, the National Academies of Sciences, Engineering, and Medicine developed a comprehensive strategic plan and blueprint for action to address SCD, which highlights the need to develop new innovative therapies and to address barriers to the equitable access of approved treatments; Whereas, in 2020, the Department of Health and Human Services, in partnership with the American Society of Hematology and the Sickle in Africa Consortium and in collaboration with the World Health Organization, hosted a webinar for a joint effort to strengthen efforts to combat SCD during the coronavirus disease (commonly known as COVID–19 ) pandemic and beyond; Whereas the late Kwaku Ohene-Frempong, M.D., Professor Emeritus of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, an American Society of Hematology member who served on the Global Coalition on SCD, has been a leader in advancing the body of knowledge in SCD research, public health, and medicine, and is recognized as immeasurably benefitting thousands of children worldwide; Whereas there are emerging genetic therapy technologies, including gene editing, that can modify a patient’s own hematopoietic stem cells to enable them to generate healthy red blood cells to prevent sickle cell crises; Whereas while hematopoietic stem cell transplantation (commonly known as HSCT ) is currently the only cure for SCD, and while advancements in treatment for complications associated with SCD have been made, more research is needed to find widely available and accessible treatments and cures to help individuals with SCD; and Whereas, although June 19, 2022, has been designated as World Sickle Cell Awareness Day to increase public alertness across the United States and global community about SCD, there remains a continued need for empirical research, early detection screenings for SCD trait carriers, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions related to SCD: Now, therefore, be it

That the Senate— (1) supports the goals and ideals of World Sickle Cell Awareness Day; (2) commits to ensuring equitable access to new sickle cell disease (referred to in this resolution as SCD ) treatments by shining the light among all economic, racial, and ethnic groups to improve health outcomes for those living with SCD; (3) calls on the Department of Health and Human Services to create global policy solutions aimed at providing support for the global community and the domestic resources needed to provide access to newborn screening programs, therapeutic interventions, and support services in partnership with local governments; (4) supports eliminating barriers to equitable access for innovative SCD therapies, including cell, gene, and gene-editing therapies in the Medicare and Medicaid systems for the most vulnerable patients; (5) encourages the people of the United States and the world to hold appropriate programs, events, and activities on Sickle Cell Awareness Day to raise public awareness of SCD traits, preventative care programs, treatments, and other patient services for those suffering from SCD, complications from SCD, and conditions related to SCD; and (6) urges that the options to be considered to combat SCD not only address access to potential future curative treatments, but also address the bias that the population most affected by SCD continues to face within the United States and global healthcare systems.